Stock Taper
SCREENER COMPARE ANY 2 STOCKS
XFOR
X4 PHARMACEUTICALS, INC.
NASDAQ
$4.04
▼ DOWN 4.49% (-0.19)

KEY STATISTICS

Market Cap$381.05 M
52w High$4.83
52w Low$2.80
Dividend Yield—
Frequency—
P/E-0.89
Volume356.15K
Shares Out.94.32M

COMPANY

LEADERSHIP

Adam R. Craig
CHIEF EXECUTIVE
Adam R. Craig

COMPENSATION 2026

Salary$420,170
Stock Awards$1,081,575
Incentive Plan Pay$0
All Other Comp.$1,138,824
Total$2,640,569

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 16, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
45

PRICE TARGET

Target High$12.00
Target Low$11.00
Target Median$12.00
Target Consensus$11.67

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$2.30M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2025-04-28Reverse1:30
2019-03-14Reverse1:6

PRICE

$4.04 ▼ DOWN 4.49% (−$0.19)
OVERLAYS
$4.05$4.13$4.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.04

About X4 Pharmaceuticals, Inc.

https://www.x4pharma.com ↗

X4 Pharmaceuticals, a late-stage biopharma company in Boston, develops novel CXCR4-targeted therapies for rare diseases and cancers, with lead candidates including mavorixafor in Phase III trials.

INDUSTRY

Biotechnology

A PRODUCT X4 PHARMACEUTICALS, INC. IS KNOWN FOR

XOLREMDI® (mavorixafor)
XOLREMDI® (mavorixafor)

XOLREMDI® is the first FDA-approved once-daily oral CXCR4 antagonist for treating WHIM syndrome in patients 12 and older, mobilizing white blood cells to combat infections by targeting the disease's underlying cause.

COMPETITORS

COMPETITOR
BLRX COMPARE
KURA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License and Other Revenue$199K $297K ▲$239K ▼$6.43M ▲
Product$4.25M $0 ▼$2.47M ▲$2.37M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
48
LISTED HERE
10
RANKED BY POSITION SIZE
VTI
0.00% · 2.6M
IWM
0.01% · 2.0M
SBIO
0.20% · 116.7K
AVSC
0.01% · 103.5K
XRSG.L
0.01% · 74.0K
ZPRR.DE
0.00% · 51.2K
RSSL
0.01% · 38.2K
PRFZ
0.00% · 30.1K
URTY
0.00% · 3.3K
FSEV
0.07% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
82.47%
HOLDERS
112
TOP 12 OF 112 · RANKED BY POSITION SIZE
Blackrock Inc.
10.7M sh · $6.19M
Morgan Stanley
9.5M sh · $39.1M
Empery Asset Management, LP
9.0M sh · $35.8B
Fmr LLC
8.5M sh · $34M
Bain Capital Life Sciences Investors, LLC
8.0M sh · $32.91M
Perceptive Advisors LLC
6.7M sh · $27.83M
Saturn V Capital Management LLC
6.5M sh · $26.67M
Deep Track Capital, LP
6.3M sh · $26.18M
Vanguard Group Inc
3.4M sh · $13.69M
Braidwell LP
3.4M sh · $13.48M
Rosalind Advisors, Inc.
3.2M sh · $13.28M
Blackstone Inc.
2.7M sh · $11.08M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: PRESIDENT
Volpone John
Sale · 24.6K shares
2026-08-12
★
DIRECTOR, OFFICER: EXECUTIVE CHAIRMAN
Craig Adam R
Sale · 47.4K shares
2026-08-12
★
OFFICER: CHIEF FINANCIAL OFFICER
KIRSKE DAVID
Sale · 8.5K shares
2026-06-30
★
DIRECTOR
Gold Kelly
Purchase · 110.0K shares
2026-07-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
Stifel BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
OKUR$3.79COMPARE
INMB$2.33COMPARE
ALGS$6.91COMPARE
KPTI$1.87COMPARE
TPST$1.06COMPARE
SNTI$0.38COMPARE
SKYE$1.77COMPARE